AbbVie (NYSE:ABBV) Shares Gap Down on Disappointing Earnings

Shares of AbbVie Inc. (NYSE:ABBV) gapped down before the market opened on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $225.66, but opened at $209.78. AbbVie shares last traded at $209.4620, with a volume of 1,858,746 shares.

The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period last year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY outlook — AbbVie reported Q4 adjusted EPS of $2.71 and revenue of $16.62B, topping estimates; management gave 2026 adjusted EPS guidance of $14.37–$14.57, above consensus, supporting the view of durable profit growth. Article Title
• Positive Sentiment: Immunology momentum — Strong demand for Skyrizi (+32% Y/Y) and Rinvoq (+29% Y/Y) drove the beat and are cited by management as the engine of revenue growth, partially offsetting Humira declines. Analysts point to continued upside from these franchises. Article Title
• Positive Sentiment: Rinvoq label expansion in progress — AbbVie submitted regulatory applications for Rinvoq (upadacitinib) in vitiligo (FDA/EMA), a meaningful new indication if approved that could support longer‑term growth. Article Title
• Neutral Sentiment: Analyst positioning mixed — Some firms (e.g., Evercore) kept bullish ratings citing immunology strength and neurology upside, while others are pausing to re‑assess targets; this is keeping trading volatile. Article Title
• Negative Sentiment: Q1 guidance missed expectations — AbbVie issued Q1 2026 EPS guidance of $2.97–$3.01 versus a ~ $3.11 consensus, and revenue guidance came in below forecasts, prompting concern about near‑term growth momentum. (Company guidance update)
• Negative Sentiment: Segment weakness and diversification worries — Aesthetics (Botox/Cosmetics) and parts of oncology showed declines and some reports flag that growth is concentrated in immunology; commentators warn the company may lean on M&A/IPR&D to sustain growth. Article Title
• Negative Sentiment: Investor skepticism on Rinvoq contribution and valuation questions — Some coverage highlights that Rinvoq’s role vs. expectations (and valuation implications for the company) remains under scrutiny despite the drug’s growth. Article Title

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ABBV. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $251.50.

Institutional Investors Weigh In On AbbVie

Several large investors have recently modified their holdings of the business. Chelsea Counsel Co. acquired a new stake in AbbVie during the 3rd quarter worth approximately $26,000. Westend Capital Management LLC bought a new stake in shares of AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie during the third quarter worth $31,000. Legacy Wealth Managment LLC ID raised its holdings in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the period. Finally, WestEnd Advisors LLC lifted its position in AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Stock Performance

The firm has a market capitalization of $383.59 billion, a P/E ratio of 164.42, a PEG ratio of 0.93 and a beta of 0.35. The firm’s 50-day moving average is $223.99 and its 200 day moving average is $219.14.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.